COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. (Q38981326)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

main subject

angiogenesis inhibitor

1 reference

Lihong Xu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Janine Stevens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mary Beth Hilton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Steven Seaman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Thomas P Conrads

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Timothy D Veenstra

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Daniel Logsdon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Holly Morris

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Deborah A Swing

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Nimit L Patel

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Joseph Kalen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Diana C Haines

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Enrique Zudaire

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Brad St Croix

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

1 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

Science Translational Medicine

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

242

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

242ra84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Pharmacokinetic evaluation of axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Angiogenesis inhibitors: motivators of metastasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Cancer: The nuances of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

G16 as a universal G protein adapter: implications for agonist screening strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Cyclooxygenase-2 in cancer and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

The mechanism of action of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

The potential and rationale for COX-2 inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Why do targeted agents not work in the adjuvant setting in colon cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Mouse models of advanced spontaneous metastasis for experimental therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Antiangiogenic therapy--evolving view based on clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Emotion recollected in tranquility: lessons learned from the COX-2 saga.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

The role of anti-inflammatory drugs in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Antibodies to watch in 2013: Mid-year update

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008455

Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer

21 January 2018

1 reference

12 December 2020

Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1

1 reference

12 December 2020

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells

1 reference

12 December 2020

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

1 reference

12 December 2020

10.1126/SCITRANSLMED.3008455

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

PubMed publication ID

24964992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964992%20AND%20SRC:MED&resulttype=core&format=json